Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

被引：157

作者：

Byrski, Tomasz ^{[1
,2
]}

Dent, Rebecca ^{[3
]}

Blecharz, Pawel ^{[4
]}

Foszczynska-Kloda, Malgorzata ^{[5
]}

Gronwald, Jacek ^{[1
]}

Huzarski, Tomasz ^{[1
]}

Cybulski, Cezary ^{[1
]}

Marczyk, Elzbieta ^{[4
]}

Chrzan, Robert ^{[6
]}

Eisen, Andrea ^{[3
]}

Lubinski, Jan ^{[1
]}

Narod, Steven A. ^{[7
]}

机构：

[1] Pomeranian Med Univ, Int Hereditary Canc Ctr, Dept Genet & Pathol, PL-70204 Szczecin, Poland

[2] Pomeranian Med Univ, Clin Oncol, PL-70204 Szczecin, Poland

[3] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON M4N 3M5, Canada

[4] Curie Mem Inst, Marie Sklodowska Clin, Dept Med Oncol, PL-31115 Krakow, Poland

[5] Reg Oncol Hosp, Dept Oncol, PL-71730 Szczecin, Poland

[6] Jagiellonian Univ, Coll Med, Dept Radiol, PL-31501 Krakow, Poland

[7] Univ Toronto, Womens Coll Res Inst, Toronto, ON M5G 1N8, Canada

来源：

BREAST CANCER RESEARCH | 2012年 / 14卷 / 04期

关键词：

NEOADJUVANT CHEMOTHERAPY; BRCA1; MUTATIONS; OVARIAN-CANCER; FOUNDER MUTATIONS; YOUNG-WOMEN; TUMORS; RESISTANCE; FAMILIES; FEATURES; CARRIERS;

D O I：

10.1186/bcr3231

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: The purpose of this investigation was to evaluate the efficacy of cisplatin chemotherapy in BRCA1 mutation carriers with metastatic breast cancer. Methods: In a phase II, open-label study, 20 patients with metastatic breast cancer who carried a mutation in BRCA1 were treated with cisplatin 75 mg/m(2) intravenously every 3 weeks as part of a 21-day cycle for 6 cycles. Restaging studies to assess response were performed after cycles 2 and 6, and every three months thereafter. Results: Between July 2007 and January 2009, 20 patients were enrolled. Baseline characteristics were as follows: 65% had prior adjuvant chemotherapy, 55% had prior chemotherapy for metastatic breast cancer; mean age was 48 years (ranges 32 to 70); 30% estrogen receptor (ER) or progesterone receptor (PR)+, 70% ER/PR/Human Epidermal Growth Factor Receptor 2 (HER2)-and 0% HER2+. Overall response rate was 80%; nine patients experienced a complete clinical response (45%) and seven experienced a partial response (35%). Overall survival was 80% at one year, 60% at two years and 25% at three years. Four of the 20 patients are alive four years after initiating treatment. The median time to progression was 12 months. The median survival from the start of cisplatinum treatment was 30 months. Cisplatin-related adverse events, including nausea (50%), anemia (5%) and neutropenia (35%) were mostly mild to moderate in severity. Conclusions: This phase II study demonstrates that cisplatin chemotherapy has high activity in women with a BRCA1 mutation and metastatic breast cancer and is generally well tolerated.

引用

页数：8